Blood Biomarkers Enter the CT Triage Debate in Mild Head Injury
In the crowded emergency setting, the question is not whether every patient with a head injury needs a CT brain scan. The real problem is deciding who can safely avoid one. In a UK-based economic model published in BMJ Open, investigators examined whether blood biomarker tests could help select patients with possible traumatic brain injury for CT scanning more efficiently, with the aim of improving resource use without compromising detection of important intracranial injury.
The analysis sits squarely in a familiar clinical dilemma: mild traumatic brain injury is common, CT scanning is widely used, and only a fraction of patients will have intracranial lesions that truly alter management. Each scan consumes time, staffing, scanner access, and patient throughput. A biomarker-driven triage pathway attempts to narrow imaging to those most likely to benefit, using a blood sample as an early biological filter before the patient reaches the scanner.
Why Biomarker Triage Matters in the Emergency Department
Emergency clinicians already rely on history, examination, and decision rules to estimate risk after head injury. Yet the thresholds for imaging remain intentionally sensitive, because missing an intracranial lesion can have serious consequences. Blood biomarkers offer a different kind of signal. Instead of inferring injury from symptoms alone, they aim to detect biochemical evidence of brain injury or tissue disruption, potentially identifying patients with a low enough risk to defer CT safely.
The economic appeal is straightforward. If a biomarker strategy can reduce avoidable scans while preserving diagnosis of clinically important lesions, it could save money, ease ED crowding, and reduce radiation exposure. In practice, any such pathway must perform well across the full spectrum of mild traumatic brain injury, including neurosurgical and non-neurosurgical lesions, because imaging decisions are made before lesion severity is known.
Model Inputs Drove the Economic Question
The study used an economic model built around UK practice. Diagnostic accuracy estimates for current biomarker tests came from a large prospective multinational cohort, the Collaborative European Neurotrauma Effectiveness Research Mild Traumatic Brain Injury study. Those estimates anchored the model’s assumptions about how well biomarker strategies identify patients with intracranial injury.
Clinical expertise informed the structure of the model so it would reflect the realities of emergency care while remaining transparent. That design choice matters because cost-effectiveness work in head injury lives or dies on workflow realism. A theoretically elegant test that cannot fit the pace of acute care has little value. Conversely, a modestly accurate test that can be deployed quickly at the bedside may alter CT use substantially.
The model examined diagnostic strategies in a way that captured the complexities of the clinical problem, but several assumptions were necessary because direct evidence was incomplete. In particular, sensitivity and specificity estimates for the diagnostic strategies were assumed to be identical for detecting neurosurgical and non-neurosurgical lesions. The model also assumed the same long-term mortality risk for patients with and without intracranial lesions, regardless of whether treatment was prompt or delayed.
One-Sentence Reality Check
A biomarker strategy can only be as strong as the assumptions that support it.
That becomes especially important when a model tries to translate test performance into downstream costs, admissions, and outcomes. Small changes in specificity can push large numbers of patients toward or away from CT, and even modest shifts in sensitivity can alter the balance between missed injury and unnecessary imaging. In a mild traumatic brain injury pathway, those tradeoffs are not abstract. They are felt in ambulance handoffs, emergency bays, radiology queues, and neurosurgical referral decisions.
What the Model Did Not Capture
Every economic model leaves some real-world behavior outside the frame. Here, the analysis did not consider that patients with negative CT or biomarker results could still require hospital admission because of other injuries or illnesses. That omission is clinically relevant because head injury rarely occurs in isolation. Polytrauma, intoxication, anticoagulant use, social concerns, or concurrent medical problems can all determine whether a patient goes home even when the brain scan is reassuring.
The assumption regarding long-term mortality is equally important. By treating mortality risk as the same in patients with and without intracranial lesions, and independent of prompt versus delayed treatment, the model simplifies a pathway in which timing may influence neurologic outcomes for some lesions. Such simplification is common in early modeling work, but it should be read as a methodologic boundary, not a biological statement.
Practical Implications for UK Head Injury Pathways
For UK emergency services, the potential value of biomarker testing lies in triage efficiency. A valid blood test could be deployed early in the care pathway to stratify risk and reduce unnecessary CT use in selected patients with mild traumatic brain injury. That kind of strategy could matter most in settings where scanner access is constrained or where the cumulative burden of low-yield scans is high.
At the bedside, the question is not whether biomarkers can replace clinical judgment. They cannot. The more relevant issue is whether they can sharpen judgment enough to improve the flow of care. If a test can reliably separate higher-risk patients from those with little likelihood of intracranial injury, it becomes a tool for decision support rather than a substitute for clinical assessment.
The study’s dependence on multinational diagnostic data strengthens confidence in the accuracy inputs, but the modeling assumptions still leave open key questions about how the strategy performs across different lesion types and clinical circumstances. Emergency medicine is filled with patients who do not fit cleanly into tidy cohorts. Real-world implementation would have to account for those edge cases, especially when other injuries or non-neurologic reasons for admission are present.
Cost-Effectiveness Hinges on What Happens After the Blood Test
Economic credibility in head injury does not come from test performance alone. It comes from the full pathway: who gets tested, who proceeds to CT, who is observed, who is admitted, and who is missed. Because this model did not include admissions for other reasons after a negative biomarker or CT result, its estimate of downstream resource use may be conservative or incomplete depending on local practice patterns.
The report also leaves unresolved the extent to which differential performance between neurosurgical and non-neurosurgical lesions could shift the economics. If a test performs better for one lesion class than another, then its utility will depend on the mix of patients in the emergency department. A test that is adequate for identifying larger, actionable lesions but weaker for smaller injuries may still alter resource use, but its cost-effectiveness would vary with local case mix and acceptable risk thresholds.
What emerges from the modeling exercise is not a final verdict, but a structured case for further evaluation. Blood biomarkers may help reduce unnecessary CT scanning in mild traumatic brain injury, yet the value of that approach depends on assumptions about lesion detection, treatment timing, and real-world admission practices. Until prospective implementation data answer those points more directly, the case for routine adoption remains tied to modeled projections rather than observed system-wide outcomes.